The benefits of PCV in oligodendroglioma, for example, are accrued mostly by patients with IDH-mutant and 1p/19q-codeleted tumors, and the benefits of PCV over radiotherapy are limited to IDH-mutant disease (136, 159). The gene discussed is IDH1; the disease is oligodendroglioma.